$836.95 travel Payment -- Merck & Co to Dr. Christopher Clark

Merck & Co covers travel and lodging for Endocrinology specialist Dr. Clark related to Opdivo

This page provides a detailed analysis of a $836.95 travel payment from Merck & Co to Dr. Christopher Clark. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$836.95
Payment Typetravel
Payment NatureTravel and Lodging
Pharmaceutical CompanyMerck & Co
PhysicianDr. Christopher Clark
NPI Number1122673583
Physician SpecialtyEndocrinology
LocationPhiladelphia, PA
Date of Payment2024-10-18
Related Drug/DeviceOpdivo
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Merck & Co made a $836.95 travel payment to Christopher Clark, a Endocrinology specialist in Philadelphia, PA. The payment was associated with Opdivo. The payment of $836.95 to Dr. Christopher Clark was for travel and lodging related to Opdivo. This payment was made by Merck & Co, a major pharmaceutical company. The payment occurred on October 18, 2024, in Philadelphia, PA.

Patient Guidance: What This Payment Means for You

This payment covered travel and lodging expenses, which may be related to educational events or discussions about a medication. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Travel and lodging payments for educational purposes are common in the pharmaceutical industry, particularly for specialists engaging with new treatments.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding travel Payments

Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.

Frequently Asked Questions About This Payment

What was this $836.95 payment for?

This was a travel payment of $836.95 from Merck & Co to Christopher Clark, categorized as "Travel and Lodging". It was associated with Opdivo. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Christopher Clark accept pharmaceutical money?

Yes, Christopher Clark received this $836.95 payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Christopher Clark's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this travel payment?

A travel payment of $836.95 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Endocrinology?

To compare this payment against Endocrinology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Endocrinology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Christopher Clark's relationship with Merck & Co?

The payment amount is relatively modest. This $836.95 travel payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Endocrinology?

The payment is specifically for travel and lodging, not for speaking or consulting.

What should patients do after learning about this payment?

This payment covered travel and lodging expenses, which may be related to educational events or discussions about a medication.

What else should I know about this travel payment?

The drug mentioned, Opdivo, is an immunotherapy treatment.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.